CLINICAL_TRIALS ClinicalTrials.gov record update

A Single Arm, Phase II Study of Sacituzumab Tirumotecan（Sac-TMT） Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic Triple Negative Breast Cancer (a/mTNBC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07244874
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:55.873333+00:00
Published At: 2025-11-24T00:00:00+00:00
Record Updated At: 2025-11-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["TNBC - Triple-Negative Breast Cancer", "PD-L1 Positive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-11-24"
protocolSection.identificationModule.nctId: "NCT07244874"
protocolSection.identificationModule.officialTitle: "A Single Arm, Phase II Study of Sacituzumab Tirumotecan\uff08Sac-TMT\uff09 Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic Triple Negative Breast Cancer (a/mTNBC)"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.